Neurocrine Biosciences | NBIX - Current Liabilities


Neurocrine Biosciences reported $743.4M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Cytokinetics USD 202.45M 60.31M Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Exelixis USD 405.64M 31.86M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Prothena USD 40.84M 10.59M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Repligen USD 135.83M 4.69M Dec/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025